Equibles does not estimate personal net worth.
Get an email with a short summary when Puma Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get PBYI alertsHeather Blaber has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Puma Biotechnology, Inc. on November 5, 2026. Puma Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Puma Biotechnology, Inc. includes Alan Auerbach (CEO and Board Member), Alan H. Auerbach (CEO and Board Member), Maximo Nougues (CFO) and 7 others.
“I appreciate the opportunity to share some additional insights into our marketing strategy. The marketing team is focused on continued awareness of both clinical data for Neuralink, as well as reinforcing the continued unmet need in HER2-positive early-stage breast cancer after adjuvant therapy.”
“I appreciate the opportunity to share some additional insights into our marketing strategy. The marketing team is focused on continued awareness of both clinical data for Neuralink, as well as reinforcing the continued unmet need in HER2-positive early-stage breast cancer after adjuvant therapy.”
“I appreciate the opportunity to share some additional insights into our marketing strategy. The marketing team is focused on continued awareness of both clinical data for Neuralink, as well as reinforcing the continued unmet need in HER2-positive early-stage breast cancer after adjuvant therapy.”
“I appreciate the opportunity to share some additional insights into our marketing strategy. The marketing team is focused on continued awareness of both clinical data for Neuralink, as well as reinforcing the continued unmet need and HER2-positive early-stage breast cancer after adjuvant therapy.”
Source not stated
Biotechnology · Healthcare
